NextCure Shares Surge on Positive Data for Bone Treatment

Dow Jones

2025/07/26

By Nicholas G. Miller

Shares of NextCure rose after the company said preclinical data supported its treatment of osteogenesis imperfecta, commonly called brittle bone disease.

The stock was up 16% to $6.09 on Friday. It is down 34% so far this year.

The Beltsville, Md.-based biopharmaceutical company said preclinical data showed its NC605 antibody treatment achieved improved bone microarchitecture and reduced fractures compared to anti-sclerostin treatment, another treatment for brittle bone disease.

The company said it is looking for financial support to advance NC605 to an investigational new drug submission with the FDA within 12 to 18 months.

Write to Nicholas G. Miller at nicholas.miller@wsj.com.

(END) Dow Jones Newswires

July 25, 2025 12:14 ET (16:14 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2554879957"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2554879957\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2554879957?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-26 00:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2554879957","market":"other","top_or_hot":-1,"title":"NextCure Shares Surge on Positive Data for Bone Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Nicholas G. <a href=\"https://laohu8.com/S/MLR\">Miller</a> \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of NextCure rose after the company said preclinical data supported its treatment of osteogenesis imperfecta, commonly called brittle bone disease. \n</p>\n<p>\n  The stock was up 16% to $6.09 on Friday. It is down 34% so far this year. \n</p>\n<p>\n  The Beltsville, Md.-based biopharmaceutical company said preclinical data showed its NC605 antibody treatment achieved improved bone microarchitecture and reduced fractures compared to anti-sclerostin treatment, another treatment for brittle bone disease. \n</p>\n<p>\n  The company said it is looking for financial support to advance NC605 to an investigational new drug submission with the FDA within 12 to 18 months. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 25, 2025 12:14 ET (16:14 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NextCure Shares Surge on Positive Data for Bone Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNextCure Shares Surge on Positive Data for Bone Treatment\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-07-26 00:14</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Nicholas G. <a href=\"https://laohu8.com/S/MLR\">Miller</a> \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of NextCure rose after the company said preclinical data supported its treatment of osteogenesis imperfecta, commonly called brittle bone disease. \n</p>\n<p>\n  The stock was up 16% to $6.09 on Friday. It is down 34% so far this year. \n</p>\n<p>\n  The Beltsville, Md.-based biopharmaceutical company said preclinical data showed its NC605 antibody treatment achieved improved bone microarchitecture and reduced fractures compared to anti-sclerostin treatment, another treatment for brittle bone disease. \n</p>\n<p>\n  The company said it is looking for financial support to advance NC605 to an investigational new drug submission with the FDA within 12 to 18 months. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 25, 2025 12:14 ET (16:14 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NXTC","symbol_name":"Nextcure Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2554879957","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2554879957","pubTimestamp":1753460040,"columns":[{"name":"行業數據","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of NextCure rose after the company said preclinical data supported its treatment of osteogenesis imperfecta, commonly called brittle bone disease.The stock was up 16% to $6.09 on Friday. It is down 34% so far this year.The Beltsville, Md.-based biopharmaceutical company said preclinical data showed its NC605 antibody treatment achieved improved bone microarchitecture and reduced fractures compared to anti-sclerostin treatment, another treatment for brittle bone disease.The company said it is looking for financial support to advance NC605 to an investigational new drug submission with the FDA within 12 to 18 months.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NXTC":"Nextcure Inc.","BK4139":"生物科技"},"translate_title":"NextCure股价因骨骼治疗的积极数据而飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NXTC":0.9},"content_text":"By Nicholas G. Miller\n\n\n \n\n\n  Shares of NextCure rose after the company said preclinical data supported its treatment of osteogenesis imperfecta, commonly called brittle bone disease. \n\n\n  The stock was up 16% to $6.09 on Friday. It is down 34% so far this year. \n\n\n  The Beltsville, Md.-based biopharmaceutical company said preclinical data showed its NC605 antibody treatment achieved improved bone microarchitecture and reduced fractures compared to anti-sclerostin treatment, another treatment for brittle bone disease. \n\n\n  The company said it is looking for financial support to advance NC605 to an investigational new drug submission with the FDA within 12 to 18 months. \n\n\n \n\n\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 25, 2025 12:14 ET (16:14 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}